NCT07579026 Effects of Breathing Retraining Exercises in Pregnant Females With Postural Orthostatic Tachycardia Syndrome.
| NCT ID | NCT07579026 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riphah International University |
| Condition | Orthostatic Hypotension |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2025-08-31 |
| Primary Completion | 2026-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2025-08-31 with a primary completion date of 2026-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Postural orthostatic tachycardia POTS is characterized by excessive increase in heart rate when moving from lying to standing position, often accompanied by symptoms such as dizziness, fatigue, brain fog, lightheadedness, rapid heartbeat and palpitation.it most commonly effects the females of reproductive age and can be triggered by events like viral infections, trauma and hormonal changes. During pregnancy females may experience worsening of symptoms in first trimester due to hormonal changes and decreased blood volume later on in second and third trimester the blood volume begins to increase. However, breathing exercises helps to regulate the nervous system, improves parasympathetic activity and reduce sympathetic activity. The study will be randomized clinical trial and will be conducted at Bashir hospital Sialkot and Fatima hospital Sialkot. The study will be completed in 10 months of duration after the approval of synopsis. Non probability convenience sampling will be used and 44 participants will be included in the study after randomization. The subjects will be divided into two groups. Group A (experimental group) will receive diaphragmatic breathing exercises whereas Group B (control group) will receive educational retraining whereas both groups will receive baseline treatments which includes progressive muscle relaxation techniques. The tools used for the study will be Vanderbilt orthostatic symptom score VOSS to evaluate orthostatic intolerance, blood pressure will be measured using non-invasive blood pressure measurement and pulse oximetry will be used to access the heart rate. After data completion data will be analyzed by using SPSS version 21.
Eligibility Criteria
Inclusion Criteria: * • Pregnant female between the age of 19 to 35 years. * Active standing results in a sustained increase in heart rate (HR) of at least 30 bpm or ≥120 bpm. * POTS patients with a subacute onset of lightheadedness, dizziness, and presyncope provoked by standing. * palpitations with chest discomfort, breathing difficulties, or feeling faint Exclusion Criteria: * • Uncontrolled hypertension/pre-eclampsia * cardiovascular disorder * Patients with uncontrolled diabetes * Patient with Anemia, severe heart failure and neurodegenerative diseases. * Females with the history of deep venous thrombosis.
Contact & Investigator
Masooma Saleem, MSPT WH
PRINCIPAL INVESTIGATOR
Riphah International University
Frequently Asked Questions
Who can join the NCT07579026 clinical trial?
This trial is open to female participants only, aged 19 Years or older, up to 35 Years, studying Orthostatic Hypotension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07579026 currently recruiting?
Yes, NCT07579026 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.
Where is the NCT07579026 trial being conducted?
This trial is being conducted at Sialkot, Pakistan.
Who is sponsoring the NCT07579026 clinical trial?
NCT07579026 is sponsored by Riphah International University. The principal investigator is Masooma Saleem, MSPT WH at Riphah International University. The trial plans to enroll 44 participants.